News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,904 Results
Type
Article (44252)
Company Profile (313)
Press Release (706319)
Multimedia
Podcasts (128)
Webinars (22)
Section
Business (211168)
Career Advice (2116)
Deals (36814)
Drug Delivery (141)
Drug Development (83553)
Employer Resources (176)
FDA (16922)
Job Trends (15538)
News (357801)
Policy (34151)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2640)
Accelerated approval (47)
Adcomms (28)
Allergies (177)
Alliances (51589)
ALS (214)
Alzheimer's disease (1819)
Antibody-drug conjugate (ADC) (458)
Approvals (17297)
Artificial intelligence (686)
Autoimmune disease (294)
Automation (57)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (226)
Biotechnology (188)
Bladder cancer (188)
Brain cancer (75)
Breast cancer (757)
Cancer (5876)
Cardiovascular disease (483)
Career advice (1802)
Career pathing (43)
CAR-T (336)
CDC (59)
Celiac Disease (3)
Cell therapy (914)
Cervical cancer (47)
Clinical research (72396)
Collaboration (2112)
Company closure (5)
Compensation (1398)
Complete response letters (87)
COVID-19 (2815)
CRISPR (113)
C-suite (1146)
Cystic fibrosis (157)
Data (7900)
Decentralized trials (3)
Denatured (38)
Depression (166)
Dermatology (86)
Diabetes (593)
Diagnostics (7016)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (327)
Drug pricing (219)
Drug shortages (34)
Duchenne muscular dystrophy (287)
Earnings (93828)
Editorial (69)
Employer branding (21)
Employer resources (155)
Events (122443)
Executive appointments (1108)
FDA (20674)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1737)
Gene editing (240)
Generative AI (59)
Gene therapy (742)
GLP-1 (1103)
Government (4874)
Grass and pollen (7)
Guidances (409)
Healthcare (19181)
HIV (79)
Huntington's disease (57)
IgA nephropathy (99)
Immunology and inflammation (301)
Immuno-oncology (94)
Indications (192)
Infectious disease (3153)
Inflammatory bowel disease (224)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (293)
Interviews (330)
IPO (16945)
IRA (57)
Job creations (4074)
Job search strategy (1500)
JPM (65)
Kidney cancer (19)
Labor market (100)
Layoffs (591)
Leadership (41)
Legal (8427)
Liver cancer (100)
Longevity (33)
Lung cancer (768)
Lymphoma (432)
Machine learning (62)
Management (60)
Manufacturing (1075)
MASH (193)
Medical device (14014)
Medtech (14135)
Mergers & acquisitions (21112)
Metabolic disorders (1536)
mRNA (216)
Multiple sclerosis (187)
NASH (18)
Neurodegenerative disease (420)
Neuropsychiatric disorders (109)
Neuroscience (3353)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4578)
Now hiring (78)
Obesity (723)
Opinion (312)
Ovarian cancer (221)
Pain (270)
Pancreatic cancer (301)
Parkinson's disease (361)
Partnered (34)
Patents (601)
Patient recruitment (673)
Peanut (65)
People (61612)
Pharmaceutical (85)
Pharmacy benefit managers (34)
Phase 1 (22469)
Phase 2 (31866)
Phase 3 (23845)
Pipeline (8771)
Policy (332)
Postmarket research (2659)
Preclinical (9595)
Press Release (68)
Prostate cancer (301)
Psychedelics (57)
Radiopharmaceuticals (328)
Rare diseases (1108)
Real estate (6320)
Recruiting (72)
Regulatory (26292)
Reports (57)
Research institute (2463)
Resumes & cover letters (362)
Rett syndrome (39)
RNA editing (23)
RSV (88)
Schizophrenia (185)
Series A (294)
Series B (216)
Service/supplier (11)
Sickle cell disease (115)
Special edition (26)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3790)
State (2)
Stomach cancer (19)
Supply chain (128)
Tariffs (99)
The Weekly (88)
Vaccines (1119)
Venture capital (110)
Weight loss (476)
Women's health (126)
Worklife (20)
Date
Today (123)
Last 7 days (858)
Last 30 days (3618)
Last 365 days (30649)
2026 (12593)
2025 (30677)
2024 (35760)
2023 (40626)
2022 (51797)
2021 (56326)
2020 (54789)
2019 (47396)
2018 (35767)
2017 (33135)
2016 (32661)
2015 (38614)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (806)
Alabama (93)
Alaska (7)
Arizona (355)
Arkansas (16)
Asia (42605)
Australia (6843)
California (13324)
Canada (3787)
China (1377)
Colorado (569)
Connecticut (580)
Delaware (407)
Europe (91723)
Florida (1990)
Georgia (425)
Hawaii (3)
Idaho (62)
Illinois (1070)
India (93)
Indiana (609)
Iowa (23)
Japan (548)
Kansas (132)
Kentucky (50)
Louisiana (42)
Maine (76)
Maryland (1596)
Massachusetts (9541)
Michigan (365)
Minnesota (721)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3502)
New Mexico (30)
New York (3489)
North Carolina (1705)
North Dakota (9)
Northern California (6669)
Ohio (398)
Oklahoma (24)
Oregon (46)
Pennsylvania (2685)
Puerto Rico (29)
Rhode Island (50)
South America (1179)
South Carolina (86)
South Dakota (2)
Southern California (5255)
Tennessee (210)
Texas (2118)
United States (47101)
Utah (396)
Vermont (1)
Virginia (338)
Washington D.C. (80)
Washington State (1070)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
750,904 Results for "tracon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
Press Releases
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
May 12, 2026
·
12 min read
Business
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) today announced financial results for the fourth quarter and year ended December 31, 2023.
March 5, 2024
·
9 min read
Business
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
9 min read
Deals
TRACON Pharmaceuticals Announces Reverse Stock Split - April 8, 2024
TRACON Pharmaceuticals today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company.
April 8, 2024
·
4 min read
Business
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023.
November 9, 2023
·
10 min read
Business
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
TRACON Pharmaceuticals, Inc. announced that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024.
May 7, 2024
·
2 min read
Press Releases
Arna Pharma Inc. and Slate Run Pharmaceuticals Finalize Joint Venture and Launch First Brand Product
May 14, 2026
·
3 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
May 14, 2026
·
3 min read
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals (NASDAQ: TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders), which is lower than the primary endpoint of the study of 11% ORR by BICR needed to support a biologics license application (BLA).
July 1, 2024
·
5 min read
1 of 75,091
Next
